A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
Completed · Phase 2
Conditions studied: Plaque Psoriasis
In brief
The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.
Key facts
- Study ID
- NCT05364554
- Run by
- Janssen Research & Development, LLC
- People needed
- 227
- Starts
- 2022-06-10
- Expected to finish
- 2023-09-29
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Must have completed the Week 16 visit in Protocol 77242113PSO2001
- In the opinion of the investigator, may benefit from inclusion in this long term extension (LTE) study
- Must agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during the study
- Must agree to discontinue all topical therapies that could affect psoriasis or the psoriasis area severity index (PASI) or investigator's global assessment (IGA) evaluation, other than nonmedicated emollient and salicylic acid shampoos, prior to first administration of study intervention
- Agree not to receive a live virus or live bacterial vaccination during the study, or within 4 weeks after the last administration of study intervention
You may not qualify if…
- Was permanently discontinued from study intervention in Protocol 77242113PSO2001 for any reason
- Has received any biologic therapy or experimental therapy since completion of the originating study, 77242113PSO2001
- Has received any live virus or bacterial vaccination within 12 weeks before the first administration of study intervention
- Has received the bacille Calmette-Guerin (BCG) vaccine within 12 months of the first administration of study intervention
- Currently has hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or has other clinically active liver disease, or tests positive for HBsAg or anti-HCV
Where it is running
- Renstar Medical Research — Ocala, Florida, United States
- Forcare Clinical Research Inc — Tampa, Florida, United States
- Arlington Dermatology — Rolling Meadows, Illinois, United States
- Indiana Clinical Trial Center — Plainfield, Indiana, United States
- Hamzavi Dermatology — Fort Gratiot, Michigan, United States
- Vivida Dermatology — Las Vegas, Nevada, United States
- Windsor Dermatology, PC — East Windsor, New Jersey, United States
- Oregon Dermatology and Research Center — Portland, Oregon, United States
- University of Pittsburgh Department of Dermatology — Pittsburgh, Pennsylvania, United States
- Modern Research Associates — Dallas, Texas, United States
- Center for Clinical Studies — Houston, Texas, United States
- Center for Clinical Studies — Webster, Texas, United States
- Premier Clinical Research — Spokane, Washington, United States
- Dermatrials Research — Hamilton, Ontario, Canada
- Alliance Clinical Trials — Waterloo, Ontario, Canada
- XLR8 Medical Research — Windsor, Ontario, Canada
- Innovaderm Research Inc. — Montreal, Quebec, Canada
- Centre Hospitalier Le Mans — Le Mans, France
- Hopital Charles Nicolle — Rouen, France
- HIA Sainte Anne — Toulon, France
- Fachklinik Bad Bentheim — Bad Bentheim, Germany
- ISA - Interdisciplinary Study Association GmbH — Berlin, Germany
- CRS Clinical Research Services Berlin GmbH — Berlin, Germany
- Niesmann & Othlinghaus GbR — Bochum, Germany
- Pacific Skin Institute — Sacramento, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.